Date:2/23/2010

human disease.  Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1031, LX1032, LX2931, and LX4211 and the potential therapeutic and commercial potential of LX1031, LX1032, LX2931, and LX4211. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related biology technology :

1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome